Albireo to Participate in Upcoming Investor Conferences
September 03 2019 - 8:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that Simon Harford, Chief
Financial Officer, will present at the 21st Annual Rodman &
Renshaw Global Investment Conference, sponsored by H.C. Wainwright
& Co., LLC, in New York City on Monday, September 9, 2019, at
10 a.m. EDT.
A live audio webcast of the presentation will be accessible from
the Media & Investors page of Albireo’s
website, ir.albireopharma.com. To ensure a
timely connection to the webcast, it is recommended that users
register at least 15 minutes prior to the scheduled start time. An
archived version of the webcast will be available for replay in the
Events & Presentations section of the Media & Investors
page of Albireo’s website for at least two weeks following the
event.
The company will also participate in the Ladenburg Thalmann 2019
Healthcare Conference in New York City on September 24, 2019.
About AlbireoAlbireo Pharma is a
clinical-stage biopharmaceutical company focused through its
operating subsidiary on the development of novel bile acid
modulators to treat orphan pediatric liver diseases, and other
liver and gastrointestinal diseases and disorders. Albireo’s lead
product candidate, odevixibat, is being developed to treat rare
pediatric cholestatic liver diseases and is in Phase 3 development
in its initial target indication, progressive familial intrahepatic
cholestasis (PFIC). Albireo’s clinical pipeline also includes two
Phase 2 product candidates. Elobixibat is in Phase 2 development in
NAFLD and NASH. Approved in Japan for the treatment of
chronic constipation, elobixibat is the first ileal bile acid
transporter (IBAT) inhibitor approved anywhere in the world.
Albireo was spun out from AstraZeneca in
2008. Albireo Pharma is located in Boston, Mass.,
and its key operating subsidiary is located in Gothenburg,
Sweden. The Boston Business Journal named Albireo one of
the 2019 Best Places to Work in Massachusetts. For more
information on Albireo, please
visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC, 212-915-2568 Media Contact:
Heather Anderson, 6 Degrees, 980-938-0260,
handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024